Regeneron jumps as third-quarter results beat expectations and margins improve
Regeneron Pharmaceuticals (REGN) shares rose 11.7% after reporting third-quarter 2026 revenue of $5.116 billion, up 36% YoY, and non-GAAP EPS of $20.07. The company cited increased collaboration revenue and improved profitability. It also updated 2026 guidance, raising gross margin expectations and lowering SG&A ranges. Analysts have issued varied price targets, with a median of $730.0.
How this was made
The 30-second read
Why it matters
The market is likely repricing REGN on higher expected gross margin and lower selling expenses for 2026, supported by strong Q3 revenue growth and EPS improvement.
Market read
A same-day, company-specific earnings beat and explicit guidance changes provide a direct catalyst for traders managing biotech earnings and margin expectations.
What to watch
The guidance improvement is tied to Sanofi Development Balance repayment effects; traders may discount durability if collaboration revenue timing normalizes again.
Background
The piece frames Regeneron’s rally as a beat-and-raise quarter, emphasizing Sanofi collaboration revenue stepping up after a balance repayment and improved profitability.
Ticker impact
Regeneron shares jump after its Q3 results beat expectations, with collaboration revenue up and updated 2026 guidance lifting gross margin and lowering SG&A ranges.
Likely further upside or volatility as the market digests the raised 2026 gross margin and expense outlook.
The article attributes the same-day rally to specific, company-issued Q3 revenue/EPS outperformance and explicit guidance changes (gross margin up, SG&A down) tied to Sanofi collaboration revenue normalization.
Market effects
Biopharma investors may broaden focus on profitability and collaboration revenue normalization, not just top-line growth.
Limited, primarily US large-cap biotech sentiment.
Moderate, as Sanofi collaboration dynamics can influence broader European-US pharma read-throughs.
Counterpoint
Product trends are described as mixed, with continued declines in legacy EYLEA potentially offsetting gains in newer franchises.
Key entities
- companyRegeneron Pharmaceuticals
Subject of the article, with Q3 results beat and updated 2026 guidance driving the stock move.
- companySanofi
Collaboration partner whose Development Balance repayment is cited as a driver of higher collaboration revenue in Q3.
- productDupixent
Regeneron product with global sales growth cited as +35% in Q3.
- productEYLEA HD
Regeneron product with sales growth cited as +63% in Q3.
- productLibtayo
Regeneron product with sales growth cited as +44% in Q3.
